Author

B. R. Weeder

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:comparative / phylogenetic analysis· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Nellore· 2 shared J. K. David· 2 shared R. F. Thompson· 2 shared A. Foley· 1 shared A. R. Leonti· 1 shared B. Davis· 1 shared B. Garcia· 1 shared B. J. Druker· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Nellore

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Burden of tumor mutations, neoepitopes, and other variants are dubious predictors of cancer immunotherapy response and overall survival

M. A. Wood, B. R. Weeder, J. K. David, A. Nellore, R. F. Thompson

This study evaluates tumor mutational burden (TMB) and related metrics as predictors of immunotherapy response and survival, finding limited predictive value in some cancers and instability in its use.

bioRxiv · Jan 28, 2020Cancer Biology

Putatively cancer-specific alternative splicing is shared across patients and present in developmental and other non-cancer cells

J. K. David, S. K. Maden, B. R. Weeder, R. F. Thompson, A. Nellore

The paper analyzes RNA-seq data to show that many cancer-specific splicing events are also present in non-cancer tissues and developmental cells, suggesting they may not be unique to cancer.

bioRxiv · Sep 5, 2019Cancer Biology

Myeloid Lineage Enhancers Drive Oncogene Synergy in CEBPA/CSF3R Mutant Acute Myeloid Leukemia

T. P. Braun, M. Okhovat, C. Coblentz, S. A. Carratt, A. Foley, Z. Schonrock, K. Nevonen, B. Davis, B. Garcia, D. LaTocha, B. R. Weeder, M. R. Grzadkowski, J. C. Estabrook, H. G. Manning, K. Watanabe-Smith, , J. E. Maxson

The paper identifies mutation synergy between CSF3R and CEBPA in AML, showing their interaction at myeloid lineage enhancers and the requirement of CEBPA mutations as an initial event.

bioRxiv · May 15, 2019Cancer Biology